Veristat Appoints New Chief Commercial Officer
May 23 2024 - 8:42AM
Business Wire
Building on its Momentum as a Global
Full-Service Clinical Research Organization (CRO) and
Consultancy
Veristat, the Science-First Full Service CRO and Consultancy,
announced an appointment to its executive leadership team. Rachel
Page joins Veristat as Chief Commercial Officer (CCO), succeeding
Veristat’s longtime leader Cindy Henderson, who recently
transitioned to become Chief Strategy Officer (CSO) to focus on
developing and executing Veristat’s customer-driven corporate
strategy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240523499154/en/
Rachel Page, Chief Commercial Officer,
Veristat (Photo: Business Wire)
With over two decades of experience in global health and science
commercialization, Rachel is poised to energize our brand and
leverage our deep industry expertise. Her role will be crucial in
assisting biopharmaceutical companies as they navigate their most
complex clinical and regulatory challenges to speed the delivery of
innovative therapies.
“Veristat has a 30-year history of driving innovative approaches
that help deliver what are often breakthrough therapies to patients
in need,” stated Patrick Flanagan, Chief Executive Officer.
“Rachel’s accomplishments and experience empowering people,
building commercial organizations, and fostering trusted client
relationships demonstrate her ability to successfully lead the
execution of our strategic plan. Rachel has received tremendous
recognition for her unwavering commitment to client success. I am
confident in her ability to leverage Veristat’s deep industry
experience on a global scale.”
Rachel’s extensive global network and her successful history in
all phases of the pharmaceutical lifecycle will be instrumental in
delivering impactful results for our clients.
"I am thrilled to join this dynamic, science-driven team,"
Rachel commented. "Veristat is exceptional at facilitating the
delivery of crucial therapies and transforming client operations. I
am honored to collaborate with such a passionate group of
executives, colleagues, and clients who are dedicated to
accelerating the availability of groundbreaking treatments for
patients with complex conditions. I am eager to lead our talented
global commercial team and contribute to achieving our clients’
vital objectives."
In her new role, Rachel will oversee Veristat’s
commercialization strategy and operations, including business
development, proposals, contracts, marketing, and fostering robust
client relationships. She will also focus on the growth and
development of the commercial team, ensuring continued success in
meeting our clients’ needs.
About Veristat
Veristat is the Science-First CRO™ and Consultancy that
integrates full service clinical trial execution, regulatory
affairs and safety, and strategic advisor services to rapidly
advance the development, approval, and commercialization of novel
therapies (#NovelTherapies) around the globe. With 30 years of
experience solving sponsors' unique and complex clinical,
statistical, and regulatory challenges, Veristat Science-First
experts deliver timely, quality-driven results with solutions that
are tailored to the needs of patients, clinical trial sites,
regulators, sponsor teams, and key stakeholders.
Veristat's focus on novel drug development has led to success
when handling any unknown that arises, from the simplest to most
complex, across numerous therapeutic areas including
rare/ultra-rare disease, advanced therapies, oncology, and
biologics including cell and gene therapies (#cellandgenetherapy),
enabling sponsors to succeed in extending and saving patients’
lives. Sponsors collaborate with Veristat Science-First experts who
care— like they do. It is not just business for Veristat, it’s
personal.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523499154/en/
Veristat: Lauren L. Brennan, Vice President of Marketing,
Veristat media@veristat.com